Tiglar 60 mg (Ticagrelor)

Adult dose

This medicine should not be used concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg once, followed by 90mg twice daily. Treatment is recommended for 12 months unless discontinuation of this medicine is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. In patients with acute coronary syndrome who have an increased risk of bleeding and have undergone percutaneous coronary intervention (PCI), monotherapy with this medicine (discontinuation of aspirin) may be considered after 3 months of concomitant treatment with this medicine and aspirin. (See 3. Use with caution in the following patients.) Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Patients who took this medicine 90mg or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with this medicine 60mg. - Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). - The safety and efficacy of this medicine were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - For patients with acute coronary syndrome, refer to the corresponding dosage and administration. - Data on the safety and efficacy of this medicine when administered for more than 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg once, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. Administration of an initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is for oral administration and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink it immediately. Rinse the cup with another half glass of water and drink it. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the tube with water after administration. When switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and there is limited experience with its use in patients with moderate hepatic impairment.

Child dose

The safety and efficacy have not been established in pediatric patients under 18 years of age (see the 'Other' section).

This medication is used to prevent blood clots by inhibiting platelet aggregation. However, it can increase the risk of bleeding; therefore, caution is required. It should not be used in patients with ongoing bleeding or a history of intracranial hemorrhage. If surgery is planned, this drug should be discontinued at least 5 days before the procedure. If signs of hypotension occur during treatment, bleeding should be suspected and medical personnel should be informed immediately. Additionally, this drug is not administered to patients with severely impaired liver function or those who are allergic to any of its components. Special caution is needed in patients at high risk of bleeding or those taking other medications that increase bleeding risk. During treatment, symptoms such as dyspnea, dizziness, and bradycardia (slow heart rate) may occur, and any such symptoms should be reported immediately. Women who are pregnant or breastfeeding should avoid this medication, and women of childbearing potential should use appropriate contraception to avoid pregnancy. Its safety and efficacy in patients under 18 years of age have not been established. In case of overdose, the risk of bleeding increases, and since there is no specific antidote, immediate medical treatment is required. Continuous vigilant monitoring for bleeding symptoms and adverse reactions is necessary during treatment.

Hemorrhage, intracranial hemorrhage, ocular hemorrhage, ear hemorrhage, hypotension, dyspnea, respiratory tract hemorrhage, gastrointestinal hemorrhage, diarrhea, nausea, dyspepsia, constipation, retroperitoneal hemorrhage, skin hemorrhage, rash, pruritus, muscle hemorrhage, urinary tract hemorrhage, genital hemorrhage, post-procedural hemorrhage, traumatic hemorrhage, thrombotic thrombocytopenic purpura, bradyarrhythmia, atrioventricular block, angioedema, Cheyne-Stokes respiration including central sleep apnea, confusion, dizziness, syncope, headache, vertigo, ear hemorrhage, melena, vomiting, chest pain, pulmonary hemorrhage, pneumonia, pulmonary edema, pharyngitis, upper respiratory infection, asthma, pleural effusion, bronchitis, pneumothorax, weakness, anaphylactic shock, hematoma, cerebral hemorrhage, spinal canal stenosis, dementia, migraine, paralysis, gait abnormalities, rectal hemorrhage, anal hemorrhage, appendicitis, connective tissue disease, bursitis, rhabdomyolysis, hepatitis, snoring, aneurysm, heart failure, palpitations, ventricular tachycardia, arrhythmia, ventricular fibrillation, cardiac arrest, ventricular fibrillation, urinary tract infection, kidney stones, cerebral ischemia, venous stenosis, cerebral infarction, arterial stenosis, angina pectoris, coronary thrombosis, myocardial ischemia, fungal infection, anemia, vestibular disorder, malignant neoplasm of the male reproductive system, chemical poisoning, post-procedural hematoma, laceration, road traffic accident, trauma, increased sputum, bronchiectasis, sleep apnea, pulmonary congestion, oral edema, flu-like syndrome, tuberculosis infection, hyperthermia, unspecified hernia, shortness of breath, generalized edema, thrombosis, deep vein thrombosis, cardiac thrombus, coagulopathy, thrombocytosis, speech disorder, cerebral hypoxia, scalp tenderness, peripheral neuropathy, neck stiffness, voice disorder, seizures, neuropathy, neuralgia, movement disorders, tremors, lower limb paralysis, coma, sensory loss, oral pain, gastroenteritis, belching, irritable bowel syndrome, stomatitis, ulcerative stomatitis, benign gastrointestinal neoplasm, dental disease, tongue disease, tendinitis, arthrosis, chondrocalcinosis, spondyloarthritis, arthritis, contact dermatitis, fungal dermatitis, skin disease, erythematous rash, keratosis, acute urticaria, onychomycosis, hair loss, scleroderma, dermatofibroma, increased sweating, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, lipodystrophy, dehydration, hepatitis, cholelithiasis, gallbladder disease, increased alkaline phosphatase, fatty liver, drowsiness, neurosis, depression, hallucinations, memory disturbances, erectile dysfunction, anxiety, orthostatic hypotension, exacerbation of hypertension, cyanosis, atrial fibrillation, cardiac arrest, complete heart block, urinary incontinence, nocturia, exacerbation of chronic renal failure, cystitis, urinary abnormalities, renal cyst, benign renal neoplasm, urinary retention, conjunctivitis, diabetic retinopathy, cataract, cardiomyopathy, cardiac compression, cardiac effusion, abscess, oral candidiasis, herpes zoster, bacterial infection, esophageal candidiasis, blood iron deficiency, tinnitus, ear pain, lymphadenopathy, eosinophilia, leukocytosis, sexual dysfunction, benign prostatic hyperplasia, ovarian cyst, amenorrhea, vaginitis, loss of taste, altered sense of smell, increased TSH, hypothyroidism, injection site reaction, injection site pain, concussion, intervertebral disc disease, non-drug allergy, deviated septum, surgical site reaction

This medication should be stored in a tightly sealed container as it may be sensitive to air and moisture. It is recommended to maintain the storage temperature between 1 degree and 30 degrees Celsius. Proper storage helps maintain the medication's efficacy over time.

Appearance

Pink, double convex, round film-coated tablet

Package unit

60 tablets/PTP (10 tablets/PTP x 6)